Vimseltinib
Vimseltinib is listed in the FDA National Drug Code directory with 6 NDC codes, marketed under brand name including ROMVIMZA. Available dosage form: capsule.
Drug Details
- Generic Name
- Vimseltinib
- Brand Names
- ROMVIMZA
- Application Number
- NDA219304
- Sponsor
- Deciphera Pharmaceuticals, LLC
- NDC Codes
- 6
- Dosage Forms
- CAPSULE
- Routes
- ORAL
- Active Ingredients
- VIMSELTINIB
Indications and Usage
1 INDICATIONS AND USAGE ROMVIMZA is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. ROMVIMZA is a kinase inhibitor indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. ( 1 )